Laboratory Medicine ›› 2020, Vol. 35 ›› Issue (11): 1197-1198.DOI: 10.3969/j.issn.1673-8640.2020.11.026
Previous Articles Next Articles
Received:2019-11-23
Online:2020-11-30
Published:2020-12-01
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2020.11.026
| [1] | United States Food and Drug Admiuistration. FDA drug safety communication:low magnesium levels can be associated with long-term use of proton pump inhibitor drugs [EB/OL]. (2011-03-02)[2019-11-22]. |
| [2] | Australian Government Department of Health and Ageing Therapeutic Goods Administration. Risk of hypomagnesaemia with proton pump inhibitors[EB/OL]. (2011-06-01)[2019-11-22]. |
| [3] | 警惕质子泵抑制剂的骨折、低镁血症风险以及与氯吡格雷的相互作用[J]. 中国医药导刊,2013,15(7):1270. |
| [4] | CHEN J,YUAN Y C,LEONTIADIS G I,et al. Recent safety concerns with proton pump inhibitors[J]. J Clin Gastroenterol,2012,46(2):93-114. |
| [5] | FERNÁNDEZ-FERNÁNDEZ F J,SESMA P,CAÍNZOS-ROMERO T,et al. Hypomagnesemia related to the use of omeprazole with negative result for mutation in the TRPM6 gene[J]. Med Clin(Barc),2011,137(4):188-189. |
| [6] | 闫伟,李玉峰,钱赓,等. 老年人药源性低血钾误诊及诊治1例[J]. 中华老年多器官疾病杂志,2016,15(11):856-857. |
| [7] | MACKAY J D,BLADON P T.Hypomagnesaemia due to proton-pump inhibitor therapy:a clinical case series[J]. QJM,2010,103(6):387-395. |
| [8] | 刘改芳. 长期应用质子泵抑制剂与低镁血症[J]. 中华消化杂志,2013,33(7):497-499. |
| [1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
| [2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
| [3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
| [4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
| [5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
| [6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
| [7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
| [8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
| [9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
| [10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
| [11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
| [12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
| [14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
| [15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
